AMOEBA (EPA:ALMIB) - ORDINARY AND EXTRAORDINARY ANNUAL GENERAL MEETING TO BE HELD ON 14th JANUARY 2019 MODALITIES THROUGH WHICH THE PREPARATORY DOCUMENTS WILL BE MADE AVAILABLE

Transparency directive : regulatory news

28/12/2018 17:45

PRESS RELEASE

Chassieu, 28th December 2018

ORDINARY AND EXTRAORDINARY ANNUAL GENERAL MEETING TO BE HELD ON 14th JANUARY
                                    2019
MODALITIES THROUGH WHICH THE PREPARATORY DOCUMENTS WILL BE MADE AVAILABLE

The company's shareholders are invited to attend the ordinary and extraordinary
annual general meetings which will be held on:

                      Monday 14th January 2019 - 10 am
At the company registered office - 38 Avenue des Frères Montgolfier- 69680
CHASSIEU

The notice of the meeting, including the agenda and the planned resolutions,
was published in the BALO (Bulletin of obligatory legal announcements) of 7th
December 2018; the notice convening the meeting was published in the BALO of
28th December 2018.

The documents stipulated by article R.225-83 of the French commercial code are
available to shareholders from the moment that the assembly is convened, in
line with the applicable regulatory requirements:

* Any named shareholder can, until the fifth day (inclusive) before the
  assembly, ask the company to send them these documents. For holders of bearer
  shares, this right can only be exercised upon presentation of a statement of
  participation in the accounts of bearer shares held by the authorised
  intermediary;

* Any shareholder can consult these documents at the company's headquarters
  during the 15 days preceding the date of the assembly.

About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on the compartment C of Euronext
Paris. The Company is a member of the BPIfrance Excellence network and is
eligible for the PEA-PME SME equity savings plan setup. More information on
www.amoeba-biocide.com.

(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
      MarketsandMarkets
(3):  BCC Research, "Markets for Advanced Wound Management Technologies,"
      Wellesley, MA, 2017
(4):  Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts :

Amoéba
Valérie FILIATRE
Directeur administratif et Financier
04 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Actifin
Ghislaine GASPARETTO
Communication financière
01 56 88 11 11
ggasparetto@actifin.fr

AMOEBA's latest news

28/03/2024 18:30

AMOEBA (EPA:ALMIB) - ORDINARY AND EXTRAORDINARY ANNUAL GENERAL MEETING TO BE HELD ON 14th JANUARY 2019 MODALITIES THROUGH WHICH THE PREPARATORY DOCUMENTS WILL BE MADE AVAILABLE

Transparency directive : regulatory news

AMOEBA's latest news

Other stories